News Roundup: COVID-19 Vaccine Antibody Response in Fully Vaccinated Patients With Cancer, Empagliflozin Reduces Risk of CV Death, Hospitalization for Heart Failure

Here’s a roundup of the latest news coverage from Drug Topics®.

Don’t waste time digging through articles to find the most up-to-date and important news. Drug Topics® has you covered with our weekly news roundup of the latest pharmacy-related news you should know before the weekend begins.

Here’s a roundup of the latest news coverage from Drug Topics®.

Empagliflozin Reduces Risk of CV Death, Hospitalization for Heart Failure With Preserved Ejection Fraction

The EMPEROR-Preserved study investigated empagliflozin (Jardiance; Eli Lilly) for the treatment of heart failure with preserved ejection fraction.

Read more

COVID-19 Antibody Response in Fully Vaccinated Patients With Cancer

Patients with cancer with complete COVID-19 vaccinations demonstrated a high rate of antibodies, according to the study.

Read more

The Successes and Challenges of the Diabetes Prevention Program in California Medi-Cal

Kenrik Duru, MD, MSHS presented a model of future projections of Medi-Cal on Diabetes Prevention Programs through current performance measures and struggles identified.

Read more

Education Can Help Mitigate Parental Concern Over Flu Vaccination for Children With Diabetes

Educating families to alleviate fear in pediatric populations regarding the flu vaccine will improve the vaccination rate and protect high-risk children. Due to the negative effects of the flu in children with diabetes, it is vital that at-risk youth be vaccinated.

Read more

New Diversity Policy Adopted by American Medical Association

The policy is part of the organization’s commitment to racial justice and equity.

Read more on Contemporary Pediatrics

Novel Antifungal Treatment Approved for Vaginal Candidiasis

On June 2, 2021, ibrexafungerp (Brexafemme; Scynexis, Inc) was approved by the Food and Drug Administration for vulvovaginal candidiasis (VVC) in adult women and pediatric females who have begun menstruating. Ibrexafungerp is a triterpenoid antifungal that works by inhibiting the formation of the fungal cell wall. Ibrexafungerp (pronounced eye-BREX-ah-FUN-jerp) is the first approved drug of a novel class of antifungals.

Read more on Contemporary OBGYN

Pharma Makers Hike Drug Prices 3.1% in July

The biggest price increase was a 9.5% rise for Zogenix’s Fintepla (fenfluramine), used to treat seizures associated with Dravet syndrome.

Read more on Managed Healthcare Executive